2022 EBMT China Voice Compared with sibling congruent transplants, haploidentical transplants achieve better quality of life without compromising survival

Hematopoietic stem cell transplantation (HSCT) provides long-term survival for most patients with blood disorders
.

Recently, an increasing number of patients have achieved better survival by receiving haploidentical transplantation (HID HSCT), but it remains unclear whether the long-term quality of life (QoL) of these patients is comparable to that of patients receiving sibling-identical transplantation (MSD HSCT) quite
.

Researchers from the Hospital of Hematology, Chinese Academy of Medical Sciences conducted a study to establish a well-established QoL assessment system and explore the differences in long-term QoL between MSD HSCT and HID HSCT
.

Methods We prospectively recruited patients who underwent allo-HSCT at the Hematology Hospital of the Chinese Academy of Medical Sciences and the Hematopoietic Stem Cell Transplantation Center of Peking Union Medical College (CAMS&PUMC) from January 2018 to December 2019
.

Patients who survived for more than one year after HSCT were informed of the purpose of the study and asked to fill out QoL questionnaires, including the Short Form Health Questionnaire (SF-36) scale and the Functional Assessment System for Cancer Therapy Scale for Quality of Life in Bone Marrow Transplantation (FACT- BMT, 3rd edition)
.

SF-36 scale from Physiological Function (PF), Physiological Function (RP), Physical Pain (BP), General Health (GH), Energy (VT), Social Function (SF), Emotional Function (RE) and Mental Health (ME) 8 aspects comprehensively summarize respondents' QoL
.

The subscales used in FACT-BMT include physical status (PWB), functional status (FWB), social status (SWB), and emotional status (EWB)
.

Patients completed the questionnaire using an online applet named HSCT-QoL-CLOUD designed by the researcher unit, and the database can be stored and exported in the cloud
.

RESULTS: This study included 425 patients who underwent allo-HSCT, and 279 surviving patients (mean age: 36.
10±11.
76, 49.
10% women) underwent QoL assessment
.

Of the included patients, 97 received HID HSCT and 182 received MSD HSCT
.

In this study, endpoints included differences in survival and QoL between the HID and MDS groups
.

During the follow-up period (median follow-up 8 months, interquartile range: 4-19 months), the estimated survival time of patients in the HID and MSD groups was 35.
2 months and 35.
3 months, respectively
.

The COX model showed that the HR for mortality was 0.
77 (95%CI: 0.
37-1.
61) in the HID group compared with the MSD group
.

In the QoL analysis, patients in the HID group had higher overall FACT (β=4.
46, 95%CI: 1.
08-7.
83) scores and higher PWB (β=1.
32, 95%CI: 0.
04-2.
59), SWB (β=1.
32, 95%CI: 0.
04-2.
59) scores =1.
57, 95%CI: 0.
54-2.
61), FWB (β=1.
51, 95%CI: 0.
22-2.
80) and TOI (β=2.
43, 95%CI: 0.
17-4.
68) scores
.

Using the SF-36 scale, it was found that compared with MSD patients, HID patients had significantly higher GH (β=5.
50, 95%CI: 0.
25-10.
75) and VT (β=4.
22, 95%CI: 0.
15-8.
30) scores
.

There was no significant difference in QoL over time between HID and MSD (all P values ​​> 0.
05)
.

In conclusion, this study shows that patients undergoing HID HSCT achieved better QoL on certain subscales compared with MSD HSCT, without compromising survival
.

Furthermore, both QoL questionnaires focus on different aspects of quality of life and neither can be substituted
.

Reference source: X.
Zhang, J.
Wang, Y.
Liu, et al.
HLA-HAPLO-IDENTICAL DONOR HSCT ACHIEVED BETTER QOL WITHOUT COMPROMISE OF SURVIVAL COMPARED TO HLA-MATCHED-SIBLING DONOR HSCT.
The 48th Annual Meeting of the EBMT.
Abstract OS19-4.
Editor: Quinta Review: Quinta Typesetting: Quinta pokes "read the original text", we make progress together